Patents by Inventor Leslie I. Gold
Leslie I. Gold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11723954Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: GrantFiled: May 14, 2021Date of Patent: August 15, 2023Assignee: NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20210393739Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: ApplicationFiled: May 14, 2021Publication date: December 23, 2021Applicant: New York UniversityInventors: Leslie I. GOLD, Marek Michalak
-
Patent number: 11045521Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: GrantFiled: March 4, 2019Date of Patent: June 29, 2021Assignee: NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20190343923Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: ApplicationFiled: March 4, 2019Publication date: November 14, 2019Applicant: New York UniversityInventors: Leslie I GOLD, Marek MICHALAK
-
Patent number: 10314888Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing or eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged bone and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering from delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: GrantFiled: January 22, 2016Date of Patent: June 11, 2019Assignee: New York UniversityInventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20160354438Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing or eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged bone and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering from delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: ApplicationFiled: January 22, 2016Publication date: December 8, 2016Applicants: NEW YORK UNIVERSITY, CALREGEN INC.Inventors: Leslie I. GOLD, Marek MICHALAK
-
Publication number: 20160310563Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.Type: ApplicationFiled: July 22, 2015Publication date: October 27, 2016Applicants: NEW YORK UNIVERSITY, CALREGEN INC.Inventors: Leslie I. GOLD, Marek MICHALAK
-
Patent number: 9261497Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: GrantFiled: October 16, 2013Date of Patent: February 16, 2016Assignee: New York UniversityInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Patent number: 9254310Abstract: The invention relates to therapeutic and cosmetic uses of calreticulin including reducing or eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged bone and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering from delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.Type: GrantFiled: June 17, 2011Date of Patent: February 9, 2016Assignees: NEW YORK UNIVERSITY, CALREGEN INC.Inventors: Leslie I. Gold, Marek Michalak
-
Patent number: 9095550Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.Type: GrantFiled: February 6, 2012Date of Patent: August 4, 2015Assignees: NEW YORK UNIVERSITY, CALREGEN INC.Inventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20140142120Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: ApplicationFiled: October 16, 2013Publication date: May 22, 2014Applicant: NEW YORK UNIVERSITYInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Publication number: 20130150285Abstract: Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles.Type: ApplicationFiled: June 17, 2011Publication date: June 13, 2013Applicants: CALREGEN INC., NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20130045918Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.Type: ApplicationFiled: February 6, 2012Publication date: February 21, 2013Applicants: CALREGEN INC., NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Patent number: 8129341Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.Type: GrantFiled: August 25, 2009Date of Patent: March 6, 2012Assignees: New York University, Calregen Inc.Inventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20100048484Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.Type: ApplicationFiled: August 25, 2009Publication date: February 25, 2010Applicant: New York UniversityInventor: Leslie I. Gold
-
Patent number: 6586394Abstract: This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.Type: GrantFiled: January 27, 1994Date of Patent: July 1, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 6559123Abstract: This invention is directed to a method of treating a burn or healing a wound in a mammal by administering a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide.Type: GrantFiled: August 22, 1994Date of Patent: May 6, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 5792742Abstract: Fibrin-binding molecules are provided which include at least one peptide essentially corresponding to one or both of the following portions of the natural fibronectin molecule. The first portion is that portion which includes the .sup.4 F1..sup.5 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the N-terminal 25.9 kDa proteolytic fragment. The second portion includes the .sup.10 F1..sup.11 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the C-terminal 11 kDa proteolytic fragment. Also disclosed are nucleic acid molecules encoding the fibrin-binding peptides, methods for making the peptides, methods for using the peptides in the diagnosis and treatment of cardiovascular, peripheral vascular, cerebrovascular, and other conditions associated with fibrin deposition, and assay methods for detecting a fibrin-binding molecule and for measuring fibrin.Type: GrantFiled: August 1, 1994Date of Patent: August 11, 1998Assignees: New York University, Isis Innovation Ltd.Inventors: Leslie I. Gold, Agueda A. Rostagno, Martin Baron, Iain D. Campbell, Michael J. Williams
-
Patent number: 5591716Abstract: Hyaluronan associated proteins, in particular calreticulin, promote the accelerated and relatively scarless healing of wounds. Methods for treating wounds using such proteins, and pharmaceutical compositions comprising such proteins, are provided.Type: GrantFiled: November 19, 1993Date of Patent: January 7, 1997Assignees: New York University, The General Hospital Corp.Inventors: John W. Siebert, Hari G. Garg, Leslie I. Gold